[{"id":"5785f67d-7426-474f-8db4-26190ac61b89","acronym":"RAPANK","url":"https://clinicaltrials.gov/study/NCT02536625","created_at":"2021-01-18T12:16:05.849Z","updated_at":"2024-07-02T16:36:35.038Z","phase":"","brief_title":"Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)","source_id_and_acronym":"NCT02536625 - RAPANK","lead_sponsor":"Centre Leon Berard","biomarkers":" HER-2 • GZMB • RPS6","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • GZMB • RPS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-02-04"},{"id":"d2d91677-fe2c-4e79-b8f3-95798ef44dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01058707","created_at":"2021-01-18T04:10:10.019Z","updated_at":"2024-07-02T16:36:47.003Z","phase":"Phase 1","brief_title":"Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT01058707","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" EIF4EBP1 • RPS6","pipe":"","alterations":" ","tags":["EIF4EBP1 • RPS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 01/04/2010","start_date":" 01/04/2010","primary_txt":" Primary completion: 02/07/2019","primary_completion_date":" 02/07/2019","study_txt":" Completion: 02/07/2019","study_completion_date":" 02/07/2019","last_update_posted":"2020-04-01"}]